245 related articles for article (PubMed ID: 28974548)
21. AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Weir HM; Bradbury RH; Lawson M; Rabow AA; Buttar D; Callis RJ; Curwen JO; de Almeida C; Ballard P; Hulse M; Donald CS; Feron LJ; Karoutchi G; MacFaul P; Moss T; Norman RA; Pearson SE; Tonge M; Davies G; Walker GE; Wilson Z; Rowlinson R; Powell S; Sadler C; Richmond G; Ladd B; Pazolli E; Mazzola AM; D'Cruz C; De Savi C
Cancer Res; 2016 Jun; 76(11):3307-18. PubMed ID: 27020862
[TBL] [Abstract][Full Text] [Related]
22. Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.
Shen H; Zhao L; Feng X; Xu C; Li C; Niu Y
Oncotarget; 2016 Sep; 7(37):60407-60418. PubMed ID: 27494865
[TBL] [Abstract][Full Text] [Related]
23. Secreted indicators of androgen receptor activity in breast cancer pre-clinical models.
Hanamura T; Christenson JL; O'Neill KI; Rosas E; Spoelstra NS; Williams MM; Richer JK
Breast Cancer Res; 2021 Nov; 23(1):102. PubMed ID: 34736512
[TBL] [Abstract][Full Text] [Related]
24. Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts.
Matthews SB; Sartorius CA
Horm Cancer; 2017 Feb; 8(1):4-15. PubMed ID: 27796944
[TBL] [Abstract][Full Text] [Related]
25. Androgen and AR contribute to breast cancer development and metastasis: an insight of mechanisms.
Feng J; Li L; Zhang N; Liu J; Zhang L; Gao H; Wang G; Li Y; Zhang Y; Li X; Liu D; Lu J; Huang B
Oncogene; 2017 May; 36(20):2775-2790. PubMed ID: 27893717
[TBL] [Abstract][Full Text] [Related]
26. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models.
Guo S; Zhang C; Mottamal M; Hossain A; Liu J; Wang G
Breast Cancer Res Treat; 2020 Apr; 180(2):359-368. PubMed ID: 32030569
[TBL] [Abstract][Full Text] [Related]
27. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
[TBL] [Abstract][Full Text] [Related]
28. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
[TBL] [Abstract][Full Text] [Related]
29. [Dual effects of androgens on mammary gland].
Brettes JP; Mathelin C
Bull Cancer; 2008 May; 95(5):495-502. PubMed ID: 18541513
[TBL] [Abstract][Full Text] [Related]
30. Antiandrogenic actions of medroxyprogesterone acetate on epithelial cells within normal human breast tissues cultured ex vivo.
Ochnik AM; Moore NL; Jankovic-Karasoulos T; Bianco-Miotto T; Ryan NK; Thomas MR; Birrell SN; Butler LM; Tilley WD; Hickey TE
Menopause; 2014 Jan; 21(1):79-88. PubMed ID: 23715406
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E; Conteduca V; Andreis D; Massa I; Melegari E; Sarti S; Cecconetto L; Schirone A; Bravaccini S; Serra P; Fedeli A; Maltoni R; Amadori D; De Giorgi U; Rocca A
Endocr Relat Cancer; 2016 Oct; 23(10):R485-98. PubMed ID: 27528625
[TBL] [Abstract][Full Text] [Related]
32. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
33. Combined Androgen and Estrogen Receptor Status in Breast Cancer: Treatment Prediction and Prognosis in a Population-Based Prospective Cohort.
Elebro K; Borgquist S; Simonsson M; Markkula A; Jirström K; Ingvar C; Rose C; Jernström H
Clin Cancer Res; 2015 Aug; 21(16):3640-50. PubMed ID: 25904752
[TBL] [Abstract][Full Text] [Related]
34. Relative impact of androgen and estrogen receptor activation in the effects of androgens on trabecular and cortical bone in growing male mice: a study in the androgen receptor knockout mouse model.
Venken K; De Gendt K; Boonen S; Ophoff J; Bouillon R; Swinnen JV; Verhoeven G; Vanderschueren D
J Bone Miner Res; 2006 Apr; 21(4):576-85. PubMed ID: 16598378
[TBL] [Abstract][Full Text] [Related]
35. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination.
Parisian AD; Barratt SA; Hodges-Gallagher L; Ortega FE; Peña G; Sapugay J; Robello B; Sun R; Kulp D; Palanisamy GS; Myles DC; Kushner PJ; Harmon CL
Mol Cancer Ther; 2024 Mar; 23(3):285-300. PubMed ID: 38102750
[TBL] [Abstract][Full Text] [Related]
36. Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Ray S; Johnston R; Campbell DC; Nugent S; McDade SS; Waugh D; Panov KI
Gene; 2013 Aug; 526(1):46-53. PubMed ID: 23608168
[TBL] [Abstract][Full Text] [Related]
37. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Macedo LF; Guo Z; Tilghman SL; Sabnis GJ; Qiu Y; Brodie A
Cancer Res; 2006 Aug; 66(15):7775-82. PubMed ID: 16885381
[TBL] [Abstract][Full Text] [Related]
38. Cholesterol synthesis inhibitor RO 48-8071 suppresses transcriptional activity of human estrogen and androgen receptor.
Mafuvadze B; Liang Y; Hyder SM
Oncol Rep; 2014 Oct; 32(4):1727-33. PubMed ID: 25051231
[TBL] [Abstract][Full Text] [Related]
39. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
Migliaccio A; Di Domenico M; Castoria G; Nanayakkara M; Lombardi M; de Falco A; Bilancio A; Varricchio L; Ciociola A; Auricchio F
Cancer Res; 2005 Nov; 65(22):10585-93. PubMed ID: 16288052
[TBL] [Abstract][Full Text] [Related]
40. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
